Alaunos Therapeutics Files Standard 8-K; No Major Changes Reported
Ticker: TCRT · Form: 8-K · Filed: Jan 22, 2024 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 8-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $250,000, $0.12 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, regulatory-filing, no-material-change
TL;DR
**Alaunos Therapeutics filed a routine 8-K, signaling no immediate executive or compensation changes.**
AI Summary
Alaunos Therapeutics, Inc. filed an 8-K on January 22, 2024, reporting an event that occurred on January 20, 2024. This filing is a standard 'Current Report' and indicates no major changes in leadership or compensatory arrangements, but rather confirms the company's current status and registration details. For investors, this matters because it signals a period of operational stability, with no immediate red flags regarding executive departures or significant new compensation plans that could impact the company's financial health or strategic direction.
Why It Matters
This filing indicates business as usual for Alaunos Therapeutics, Inc., suggesting stability in its corporate governance and executive team, which can be reassuring for current and prospective investors.
Risk Assessment
Risk Level: low — The filing is a routine current report with no disclosed events that would introduce new risks or significant changes to the company's operations or financial standing.
Analyst Insight
A smart investor would view this as a non-event, indicating stability rather than significant news. It suggests no immediate need to adjust investment strategy based on executive changes or compensation shifts.
Key Numbers
- 001-33038 — Commission File Number (Identifies Alaunos Therapeutics, Inc.'s registration with the SEC.)
- 84-1475642 — IRS Employer Identification No. (Standard identification for tax purposes.)
- $0.001 — par value per share (The nominal value of each share of Common Stock.)
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 20, 2024 (date) — date of the earliest event reported
- January 22, 2024 (date) — date the 8-K was filed
- Delaware (company) — state of incorporation for Alaunos Therapeutics, Inc.
- 001-33038 (dollar_amount) — Commission File Number for Alaunos Therapeutics, Inc.
- TCRT (company) — trading symbol for Common Stock of Alaunos Therapeutics, Inc.
- The Nasdaq Stock Market LLC (company) — exchange where Alaunos Therapeutics, Inc. Common Stock is registered
FAQ
What is the purpose of this 8-K filing by Alaunos Therapeutics, Inc.?
This 8-K filing is a 'Current Report' pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating that the company is reporting an event that occurred on January 20, 2024. The item information specifies 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', but the content of the filing itself does not detail any such changes, suggesting it's a routine update confirming no material changes in these areas.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 20, 2024.
What is the trading symbol and exchange for Alaunos Therapeutics, Inc.'s Common Stock?
The trading symbol for Alaunos Therapeutics, Inc.'s Common Stock is TCRT, and it is registered on The Nasdaq Stock Market LLC.
What is the state of incorporation for Alaunos Therapeutics, Inc.?
Alaunos Therapeutics, Inc. is incorporated in Delaware.
Does this 8-K filing indicate any changes in the company's executive leadership or compensation arrangements?
While the item information category for the filing is 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', the body of the filing itself does not provide any details about such changes. This suggests that there were no reportable changes in these areas as of the event date, making it a routine filing to confirm status.
Filing Stats: 818 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2024-01-22 16:30:58
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share TCRT The Nasdaq Stock Mar
- $250,000 — e will receive an annual base salary of $250,000. Mr. Hogue was granted an option to pur
- $0.12 — ompany, with an exercise price equal to $0.12. The option shall vest with respect to
Filing Documents
- d732206d8k.htm (8-K) — 24KB
- 0001193125-24-012201.txt ( ) — 143KB
- tcrt-20240120.xsd (EX-101.SCH) — 3KB
- tcrt-20240120_lab.xml (EX-101.LAB) — 18KB
- tcrt-20240120_pre.xml (EX-101.PRE) — 11KB
- d732206d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alaunos Therapeutics, Inc. Date. January 22, 2024 By: /s/ Michael Wong Name: Michael Wong Title: Vice President, Finance